全文获取类型
收费全文 | 2698篇 |
免费 | 159篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 51篇 |
妇产科学 | 67篇 |
基础医学 | 276篇 |
口腔科学 | 84篇 |
临床医学 | 228篇 |
内科学 | 885篇 |
皮肤病学 | 46篇 |
神经病学 | 289篇 |
特种医学 | 63篇 |
外科学 | 307篇 |
综合类 | 13篇 |
预防医学 | 86篇 |
眼科学 | 24篇 |
药学 | 210篇 |
肿瘤学 | 220篇 |
出版年
2023年 | 16篇 |
2022年 | 8篇 |
2021年 | 61篇 |
2020年 | 46篇 |
2019年 | 46篇 |
2018年 | 67篇 |
2017年 | 60篇 |
2016年 | 63篇 |
2015年 | 82篇 |
2014年 | 125篇 |
2013年 | 145篇 |
2012年 | 206篇 |
2011年 | 185篇 |
2010年 | 118篇 |
2009年 | 115篇 |
2008年 | 189篇 |
2007年 | 214篇 |
2006年 | 176篇 |
2005年 | 185篇 |
2004年 | 149篇 |
2003年 | 117篇 |
2002年 | 116篇 |
2001年 | 41篇 |
2000年 | 36篇 |
1999年 | 25篇 |
1998年 | 19篇 |
1997年 | 15篇 |
1996年 | 14篇 |
1995年 | 12篇 |
1994年 | 14篇 |
1993年 | 11篇 |
1992年 | 21篇 |
1991年 | 13篇 |
1990年 | 10篇 |
1989年 | 15篇 |
1988年 | 15篇 |
1987年 | 13篇 |
1986年 | 10篇 |
1985年 | 10篇 |
1984年 | 6篇 |
1983年 | 7篇 |
1982年 | 7篇 |
1981年 | 9篇 |
1980年 | 6篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1974年 | 10篇 |
1970年 | 3篇 |
1968年 | 3篇 |
1966年 | 3篇 |
排序方式: 共有2869条查询结果,搜索用时 289 毫秒
1.
Simonetta Viviani Arabella Mazzocchi Chiara Pavoni Francesca Taverna Andrea Rossi Caterina Patti Alessandra Romano Livio Trentin Roberto Sorasio Anna Guidetti Daniela Gottardi Corrado Tarella Michele Cimminiello Roberta Zanotti Lucia Farina Andrés José Maria Ferreri Marina Galbiati Paolo Corradini Alessandro Massimo Gianni Andrea Gallamini Alessandro Rambaldi 《Hematological oncology》2020,38(4):501-508
Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation-regulated chemokine (TARC) levels, to improve risk assessment in patients treated according to HD0607 PET-driven trial (#NCT00795613). In 266 patients with available serum samples, who have agreed to participate in a sub-study for assessment of the role of TARC monitoring, serum TARC levels were measured at baseline and at time of PET-2 by commercially available ELISA test kits. The primary end-point was to evaluate the association between TARC after 2 ABVD cycles and PFS. Median TARC-2 values were significantly higher in PET-2-positive patients compared to PET-2-negative patients (P = .001), and in patients with treatment failure compared to those in continuous CR (P = .01). The 4-year PFS significantly differed between patients with TARC-2 >800 pg/mL vs ≤800 pg/mL (64% vs 86%, P = .0001). Moreover, among PET-2-negative patients, elevated TARC-2 identified those with a worse prognosis (74% vs 89%; P = .01). In multivariable analysis, TARC-2 >800 pg/mL was a significant independent predictor of PFS in the whole study population (HR 2.39, P = .004) and among the PET-2-negative patients (HR 2.49, P = .02). In conclusion, our results indicate that TARC-2 serum levels above 800 pg/mL suggest the need for a stringent follow-up in PET-2-negative patients, and the evaluation of new drugs in PET-2-positive, who will likely fail to respond to intensification with escalated BEACOPP. 相似文献
2.
3.
D. Sforza G. Iaria L. Petagna A. Parente A. Anselmo F. Sergi S. Marzio F. Corrado S. Telli T.M. Manzia G. Tisone 《Transplantation proceedings》2019,51(1):140-142
Background
One daily dose of tacrolimus (QDT) improves adherence in kidney transplant (KT) recipients. A switch from twice-daily tacrolimus (BDT) to QDT showed similar efficacy and safety.Methods
The aim of our study was to demonstrate the long-term efficacy and safety of switching from BDT to QDT in KT recipients. Preliminary results have already been published. Forty-one patients (34 men and 7 women), mean age at KT of 43.9 ± 12.7 years, underwent a 1:1 dose switch from BDT to QDT; the mean time from KT to switch was 36.6 ± 16.1 months. In our study population, 4 patients received a living donor KT and 2 received a second allograft.Results
The mean follow-up was 86.8 ± 13 months from the switch and 126.2 ± 22.3 months from KT. Graft and patient survival rates were 90.2% and 95.1%, respectively. All patients maintained stable renal function during follow-up. During the first 3 months after the switch we observed a significant decrease in tacrolimus blood level (P = .0001). No significant differences were observed regarding tacrolimus dose before and after QDT introduction (P = not significant [NS]). Fourteen patients who stopped steroids under BDT treatment and 16 patients who stopped steroids after the switch are currently steroid-free.Conclusion
Our study showed safety and efficacy in switching from BDT to QDT. After early (<1 year) dose adjustment, tacrolimus blood levels remained stable throughout follow-up. Moreover, QDT represented a valid alternative for patients showing steroid side effects. 相似文献4.
Alessandro Vatrella Angelantonio Maglio Corrado Pelaia Girolamo Pelaia Carolina Vitale 《Expert opinion on pharmacotherapy》2020,21(12):1505-1515
ABSTRACT
Introduction
‘Critical Asthma Syndrome’ (CAS) is an umbrella term proposed to include several forms of asthma, responsible for acute and life-threatening exacerbations. CAS requires urgent and adequate supportive and pharmacological treatments to prevent serious outcomes. 相似文献5.
Paola Finsinger Massimo Breccia Clara Minotti Ida Carmosino Corrado Girmenia Marta Chisini Paola Volpicelli Federico Vozella Angela Romano Chiara Montagna Gioia Colafigli Giuseppe Cimino Giuseppe Avvisati Maria Concetta Petti Francesco Lo-Coco Roberto Foà Roberto Latagliata 《Annals of hematology》2015,94(2):195-200
6.
7.
8.
9.